- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07449520
Prospektivní studie endoskopické rukávové gastroplastiky (ESG) pro obezitu (EGO-Trial)
Prospektivní studie endoskopické sleeve gastroplastiky (ESG) pro léčbu obezity
EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions
The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.
Přehled studie
Detailní popis
Obesity, particularly morbid obesity, is a major public health issue in France. According to the latest data from the ObÉpi-Roche 2020 survey, more than 17% of French adults are obese. Obesity is a well-established risk factor for many chronic diseases such as type 2 diabetes, cardiovascular disease, high blood pressure (HBP), musculoskeletal disorders, certain cancers, and non-alcoholic steatohepatitis (NASH). It is associated with a significant reduction in life expectancy and represents a direct cost estimated at more than €5 billion per year for the French healthcare system.
While bariatric surgery (particularly sleeve gastrectomy and gastric bypass) remains the gold standard treatment for severe obesity, it is invasive, costly, and only offered to a minority of patients (less than 10% of eligible patients). In addition, certain medical contraindications, refusal of surgery, and waiting times limit access to this treatment.
Endoscopic sleeve gastroplasty ("Endosleeve"). Endoscopic sleeve gastroplasty (ESG) is an innovative, non-surgical, natural procedure that reduces stomach volume without resection or anastomosis. It has shown promising results in terms of weight loss, metabolic improvement, and safety, while being reversible and reproducible. The MERIT randomized controlled trial in USA (JAMA, 2022) demonstrated an average weight loss of 13.6% of total body weight at 12 months (vs. 0.8% in the control group), as well as a significant improvement in comorbidities such as type 2 diabetes and hypertension.
Hypothesis and objective of the study The hypothesis of this study is that ESG, when performed under routine care conditions in the United States, leads to significant and sustainable weight loss, associated with an improvement in comorbidities, with a favorable safety profile. The main objective of this project is therefore to evaluate, on a national scale, the clinical efficacy, safety, and procedural variability of ESG through a multicenter real-world cohort.
To date, no large-scale French study has analyzed the results of ESG in real-world settings. This hinders its integration into national healthcare pathways, its reimbursement by the French national health insurance system, and its wider adoption by the medical community. The question raised-the rigorous evaluation of ESG in the French context-therefore remains unanswered.
This project aims to generate robust data representative of the national clinical reality in order to support the supervised development of ESG. Expected outcomes include the publication of scientific articles in peer-reviewed journals, the presentation of results at international conferences, contributions to health technology assessment work, and the establishment of a national registry of endoscopic gastroplasty. This work could represent a major advance in the therapeutic arsenal for obesity, supporting the integration of ESG as a recognized, validated, and reimbursed option in French healthcare pathways.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Armelle TAKEDA
- Telefonní číslo: 0033 390 413608
- E-mail: armelle.takeda@ihu-strasbourg.eu
Studijní záloha kontaktů
- Jméno: Clinical Research Team
- E-mail: rc-ihu@ihu-strasbourg.eu
Studijní místa
-
-
-
Aix-en-Provence, Francie
- Nábor
- Hôpital Privé de Provence
-
Kontakt:
- Hugues SEBBAG
- Telefonní číslo: 0033 4 42 21 12 11
- E-mail: hsebbag.ppr@hotmail.fr
-
Besançon, Francie
- Zatím nenabíráme
- Polyclinique de Franche-Comté
-
Kontakt:
- Henry-Alexis MERCOLI
- Telefonní číslo: 0033 3 81 41 81 41
- E-mail: docteur.mercoli@gmail.com
-
Lille, Francie
- Zatím nenabíráme
- Hôpital HURIEZ
-
Kontakt:
- Robert CAIAZZO
- Telefonní číslo: 0033 3 20 44 42 73
- E-mail: robert.caiazzo@univ-lille2.fr
-
Lyon, Francie
- Nábor
- Clinique de la Sauvegarde
-
Kontakt:
- Marie-Cécile BLANCHET
- Telefonní číslo: +33 4 37 49 70 10
- E-mail: blanchet@chirurgien-digestif.com
-
Lyon, Francie
- Nábor
- Hospices Civils de Lyon - Hôpital Edourard HERRIOT
-
Kontakt:
- Maud ROBERT
- Telefonní číslo: 0033 4 72 11 62 61
- E-mail: Maud.robert@chu-lyon.fr
-
Montpellier, Francie
- Zatím nenabíráme
- Clinique Clémentville
-
Kontakt:
- Marta SILVESTRI
- Telefonní číslo: 0033 4 67 06 70 00
- E-mail: docteur.m.silvestri@gmail.com
-
Saint-Etienne, Francie
- Zatím nenabíráme
- Centre Mutualiste de l'Obésité
-
Kontakt:
- Pierre BLANC
- Telefonní číslo: 0033 4 77 81 82 88
- E-mail: PBLANC@mutualite-loire.com
-
Saint-Grégoire, Francie
- Zatím nenabíráme
- CHP Saint-Grégoire
-
Kontakt:
- Adrien STERKERS
- Telefonní číslo: +33 2 99 23 93 10
- E-mail: asterkers@vivalto-sante.com
-
Strasbourg, Francie
- Nábor
- Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil
-
Kontakt:
- Silvana PERRETTA
- Telefonní číslo: 0033 3 69 55 05 31
- E-mail: perretta@unistra.fr
-
Sète, Francie
- Nábor
- Polyclinique Sainte Thérèse
-
Kontakt:
- Thibaut COSTE
- Telefonní číslo: 0033 4 67 18 88 20
- E-mail: thibautcoste@gmail.com
-
Échirolles, Francie
- Zatím nenabíráme
- Clnique des Cèdres
-
Kontakt:
- Fabien STENARD
- Telefonní číslo: 0033 4 56 58 14 90
- E-mail: fabien.stenard@cliniquedescedres.com
-
-
-
-
-
Baie-Mahault, Guadeloupe
- Zatím nenabíráme
- Clinique les Eaux Claires
-
Kontakt:
- Venetia AVENDANO
- Telefonní číslo: 0033 5 90 25 95 65
- E-mail: zulemacu@yahoo.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Adult patients with obesity scheduled for endoscopic gastroplasty
Popis
Inclusion Criteria:
- Patients aged 18 to 75 years.
- Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
- Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
- Patients not eligible for bariatric surgery or does not wish to undergo it.
- Patients who can undergo general anesthesia.
- Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.
- Patients who are able to fully understand the study and are willing to give their consent to participate in the study.
- Patients affiliated with the French social security system.
Exclusion Criteria:
- Patients with contraindications to endoscopic gastroplasty
- Patients with active peptic ulcer disease or significant gastroparesis
- Patients with a history of bariatric, gastric, or esophageal surgery.
- Patients who have started medication in the last 3 months that is known to cause weight gain.
- Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.
- Patients with unstable and precarious health, as determined and assessed by the investigator.
- Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.
- Patients who are currently excluded (as determined by a previous or ongoing study).
- Patients under judicial protection.
- Patients under guardianship, conservatorship or subject to any form of protective supervision
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: CASE_ONLY
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Všichni dospělí pacienti s obezitou naplánovaní na endoskopickou gastroplastiku (ESG)
|
Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device which allows for a reduction in stomach volume without resection or anastomosis |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Total Body Weight Loss
Časové okno: At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of total body weight loss (TBWL, %) 24 months after surgery |
At the inclusion and 24 months after procedure
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Excess weight loss
Časové okno: At the inclusion and 24 months after procedure
|
Assessment of weight loss in terms of excess weight loss (EWL, %) at 24 months post-procedure |
At the inclusion and 24 months after procedure
|
|
Body Mass Index (BMI)
Časové okno: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of weight loss in terms of change in Body Mass Index (BMI) at 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Adverse events
Časové okno: From ESG procedure to the end of participation at 24 months post-procedure
|
Rate of minor and major adverse events (e.g., perforation, delayed gastric emptying, reflux symptoms) throughout follow-up for up to 24 months post-procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Comorbidities improvement
Časové okno: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of improvement in comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea) and obesity-related complications over 24 months using the SF-BARI (Swiss-Finnish BARIatric metabolic outcome score) questionnaire: a score developed to evaluate treatment outcomes in obesity management |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Quality of life improvement
Časové okno: From ESG procedure to the end of participation at 24 months post-procedure
|
Assessment of quality of life over 24 months using the GIQLI (Gastrointestinal Quality of Life Index) questionnaire: digestive quality of life score comprising 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments |
From ESG procedure to the end of participation at 24 months post-procedure
|
|
Additional treatments
Časové okno: From ESG procedure to the end of participation at 24 months post-procedure
|
Compilation of additional treatments or revisions required after the procedure |
From ESG procedure to the end of participation at 24 months post-procedure
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Silvana PERRETTA, MD-PhD, Hôpitaux Universitaires de Strasbourg
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 25-004
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .